Pharmafile Logo
Pharmafocus logo
Advanced Search

David Khougazian announced as president of Sanofi Pasteur MSD

July 29, 2015
Business Services, Research and Development, Sales and Marketing MSD, Merck, Sanofi Pasteur

Sanofi Pasteur and Merck have appointed David Khougazian as president of their joint company, Sanofi Pasteur MSD. David Khougazian joined …

Appointment
dr_james_shannon

Dr James Shannon joins Immodulon Therapeutics board of directors

July 29, 2015
Research and Development, Sales and Marketing Immodulon

Dr James Shannon has joined Immodulon as a non-executive director with immediate effect. Bringing with him 30 years’ of experience …

Appointment
UCB

Mixed Phase 3 results for Sanofi and UCB

July 29, 2015
Research and Development LixiLan, Sanofi, UCB, clinical trials, epratuzumab, insulin, insulin glargine, phase III

Two drugs that pharma companies are pinning hopes on for future success have had mixed outcomes in key late-stage clinical …

News
Novartis window

Novartis forms Mereo as UK biotech spin-off

July 29, 2015
Research and Development Mereo, Novartis, biotech, rare diseases

Novartis has formed a new UK biotech company by selling three investigational drugs in exchange for shares in the new …

News
AstraZeneca plaque

Cambridge collaboration to boost precision medicine research

July 29, 2015
Research and Development Brabaham Institute, Cambridge, R&D, collaboration

A new consortium has been launched to act as a ‘match-making’ service between pharma companies and R&D researchers to develop …

News
Scales of justice

Judge rules pharma has ‘ethical’ transparency obligation – reaction

July 29, 2015
Research and Development Ben Goldacre, Richmond Pharmacology, alltrials, clinical trials, health research authority, hra, sense about science, transparency

Both sides of a bitterly contested legal battle over a major part of the industry’s transparency drive have reacted to …

News
Gavel

Judge backs HRA in transparency legal case

July 28, 2015
Research and Development EU Clinical Trial Regulation, Richmond Pharmacology, alltrials, clinical trial regulation, clinical trials, health research authority, sense about science, transparency

A judge has ruled that there are likely to be no legal grounds to block the Health Research Authority’s plans …

News
India flag

Lupin buys Gavis to gain first US manufacturing site

July 28, 2015
Manufacturing and Production Gavis, Lupin, manufacturing, production

Indian drug manufacturer Lupin is expanding to the US by purchasing Gavis pharma for $880 million, in a major boost …

News
Regeneron building

Sanofi and Regeneron in immuno-oncology push

July 28, 2015
Manufacturing and Production, Research and Development Cancer, PD-1 inhibitors, Regeneron, Sanofi, collaboration, immuno-oncology, pd-1

Pharma giants Sanofi and Regeneron are extending the partnership that brought new heart drug Praluent to the market, with a …

News
Antibiotic resistance

Rising to meet the infectious disease challenge

July 27, 2015
Manufacturing and Production, Research and Development, Sales and Marketing Antibiotics, R&D, antibiotic resistance, infectious disease

Antibiotic-resistant infections gather more headlines than most other infectious disease topics, and have typically been seen as a neglected area …

Feature
Sanofi Regeneron

FDA and EMA approve heart drug Praluent

July 27, 2015
Sales and Marketing EMA, FDA, PCSK9, Regeneron, Sanofi, high cholesterol, praluent

The FDA and the EMA have both approved Sanofi and Regeneron’s new high cholesterol drug Praluent. Regulators on both sides …

News
dr_joerg_reinhardt

Novartis Foundation confirms Dr Joerg Reinhard as new chairman

July 27, 2015
Manufacturing and Production, Medical Communications Dr Joerg Reinhardt, Novartis

The Novartis Foundation has confirmed several new members of its board of trustees, including a new chairman in Dr Joerg …

Appointment
allergan

Teva to switch generics focus to Allergan

July 27, 2015
Sales and Marketing Allergan, Teva, generics, mergers and acquisitions, pharma mergers and acquisitions

Teva is in negotiations to buy Allergan’s generics division for upwards of $40 billion, according to reports. The generics firm …

News
Novartis image

FDA approves Novartis drug Odomzo

July 27, 2015
Sales and Marketing Novartis, Odomzo, basal cell carcinoma, skin cancer

The FDA has given the Swiss firm the go-ahead to market its drug for skin cancer. Odomzo (sonidegib, formerly LDE225) …

News
Vaccination

EMA backs GSK’s malaria vaccine for use in Africa

July 24, 2015
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CHMP, Committee for Medicinal Products for Human USE, EMA, European Medicines Agency, GSK, WHO, malaria, world health organization

GSK has taken a significant step forward toward being the first company to bring a malaria vaccine to market, after …

News
EMA

EMA in push for more paediatric drug trials

July 24, 2015
Medical Communications, Research and Development EMA, European Medicines Agency, clinical trials, drug development, paediatrics

The European Medicines Agency has relaxed some of its rules around the development of drugs in children, in order to …

News
Keytruda image

European Commission approves Merck’s Keytruda for melanoma drug

July 23, 2015
Sales and Marketing

The European Commission has approved Merck’s Keytruda (pembrolizumab) as a skin cancer treatment. Keytruda, the company’s successful anti-PD-L1 therapy and …

News
MabThera

Cancer and immunology drugs drive strong Roche sales performance

July 23, 2015
Sales and Marketing Roche, Severin Schwan, financials

Sales at Roche rose 6% in the first half of 2015, buoyed by “significant growth of sales and immunology medicines”, …

News
alzheimers_brain

Lilly, Biogen and Roche debut Alzheimer’s disease drug results

July 22, 2015
Research and Development Alzheimer's, Alzheimer's disease, Biogen, Conference, Eli Lilly, Roche, lilly

Big pharma companies have posted mixed results in trials of several potential new treatments for Alzheimer’s disease. But the results, …

News
Opdivo

BMS halts Opdivo kidney cancer trial early

July 22, 2015
Research and Development BMS, Bristol-Myers Squibb, European Commission, Kidney cancer, opdivo, renal cell carcinoma

Bristol-Myers Squibb has stopped its Phase III study of its immunotherapy drug Opdivo in people with kidney cancer early after …

News
The Gateway to Local Adoption Series

Latest content

Campaign highlights low expectations among patients with depression

May 7, 2026

Practical AI toolkit launched to help manufacturers cut through complexity

May 6, 2026

Syngene appoints Maninder Kapoor Puri as CHRO

May 6, 2026

BioPhorum acquires PharmaX Solutions

May 5, 2026

Syngene appoints Abhijit Zutshi as CCO

May 5, 2026